- Home
- MIN vs SKYE Comparison
MIN vs SKYE Comparison
Compare MIN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- SKYE
- Stock Information
- Founded
- MIN 1988
- SKYE 2012
- Country
- MIN United States
- SKYE United States
- Employees
- MIN N/A
- SKYE N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- MIN Finance
- SKYE Health Care
- Exchange
- MIN Nasdaq
- SKYE Nasdaq
- Market Cap
- MIN 310.1M
- SKYE 108.3M
- IPO Year
- MIN N/A
- SKYE N/A
- Fundamental
- Price
- MIN $2.72
- SKYE $4.94
- Analyst Decision
- MIN
- SKYE Buy
- Analyst Count
- MIN 0
- SKYE 6
- Target Price
- MIN N/A
- SKYE $18.67
- AVG Volume (30 Days)
- MIN 331.0K
- SKYE 308.0K
- Earning Date
- MIN 01-01-0001
- SKYE 11-09-2024
- Dividend Yield
- MIN 7.31%
- SKYE N/A
- EPS Growth
- MIN N/A
- SKYE N/A
- EPS
- MIN 0.08
- SKYE N/A
- Revenue
- MIN N/A
- SKYE N/A
- Revenue This Year
- MIN N/A
- SKYE N/A
- Revenue Next Year
- MIN N/A
- SKYE N/A
- P/E Ratio
- MIN $33.38
- SKYE N/A
- Revenue Growth
- MIN N/A
- SKYE N/A
- 52 Week Low
- MIN $2.52
- SKYE $1.44
- 52 Week High
- MIN $2.88
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- MIN 44.73
- SKYE 58.26
- Support Level
- MIN $2.70
- SKYE $4.01
- Resistance Level
- MIN $2.74
- SKYE $5.48
- Average True Range (ATR)
- MIN 0.02
- SKYE 0.46
- MACD
- MIN -0.00
- SKYE 0.19
- Stochastic Oscillator
- MIN 22.89
- SKYE 73.79
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.